Wave Therapeutics

Cover Block

PUBLIC

Attribute	Wave Therapeutics
Name	Wave Therapeutics
Tagline	Smart therapeutic cushioning to prevent pressure injuries and blood clots in high-risk patients.
Headquarters	Nashville, Indiana, United States
Founded	2017
Stage	Seed [PitchBook, retrieved 2024]
Funding Label	Seed (total disclosed ~$1,610,000) [PitchBook, retrieved 2024]
Founding Team	Jessica Bussert, RN [LinkedIn, retrieved 2024]

Links

PUBLIC

• Website: https://wavetherapeuticsinc.com
• LinkedIn: https://www.linkedin.com/company/wavetherapeuticsinc

Executive Summary

PUBLIC

Wave Therapeutics is developing smart therapeutic cushioning to automate pressure relief and prevent costly, life-threatening injuries in immobile patients, a clinical problem that has seen limited innovation in its core intervention. The company's flagship product, the Wave Therapeutic Cushion, integrates a microprocessor-controlled pump to dynamically adjust pressure and perform sequential compression therapy, aiming to reduce the incidence of pressure injuries and blood clots [Perplexity Sonar Pro Brief, retrieved 2024]. Founder Jessica Bussert, a registered nurse and technologist, launched the company in 2017, grounding its development in frontline clinical experience [General Assembly, retrieved 2026].

Differentiation rests on combining two established medical therapies,pressure redistribution and intermittent pneumatic compression,into a single, automated device paired with a remote monitoring analytics platform [techpoint.org, retrieved 2026]. The company has secured early-stage backing from a consortium of regional funds and accelerators, including mHUB Ventures and Techstars, with total disclosed capital estimated at approximately $1.6 million [PitchBook, retrieved 2024]. Its business model targets sales to long-term care facilities and hospitals, where the value proposition centers on reducing treatment costs and liability [Perplexity Sonar Pro Brief, retrieved 2024].

Over the next 12-18 months, key milestones to watch include the transition from working prototypes to commercial manufacturing, the announcement of initial pilot deployments with named healthcare institutions, and the progression of its patent-pending technology through the regulatory pathway [ciconiamedical.com, retrieved 2026].

Data Accuracy: YELLOW -- Core product description and founder role are well-corroborated; funding totals conflict between major databases.

Taxonomy Snapshot

Axis	Value
Founding Team	Jessica Bussert, RN (Founder/CEO)
Funding	Seed (~$1.6M estimated)

Company Overview

PUBLIC

Wave Therapeutics was founded in 2017 by Jessica Bussert, a registered nurse, with the intent to develop smart cushioning technology for pressure injury prevention [PitchBook, retrieved 2024]. The company is headquartered in Nashville, Indiana, and presents itself as a woman-owned medical device startup [LinkedIn, retrieved 2024].

Key milestones trace a path through accelerator programs and early-stage funding. The company participated in the gBETA accelerator in 2021, followed by acceptance into the Techstars and mHUB Accelerator programs in subsequent years [PitchBook, retrieved 2024]. A notable seed round of $1 million was closed in July 2023, contributing to a total disclosed capital raise of approximately $1.61 million according to one source [PitchBook, retrieved 2024]. The company has also secured smaller grants, including a $20,000 business plan competition win [CB Insights, retrieved 2024].

Public development progress includes a collaboration with the Veterans Health Administration (VHA) Innovation Ecosystem on the design of an initial wheelchair seat cushion product [rehabpub.com, retrieved 2026]. The company reports its technology is patent-pending and that it is finalizing designs for manufacture with partner factories [wavetherapeuticsinc.com, retrieved 2024] [ciconiamedical.com, retrieved 2026].

Data Accuracy: YELLOW -- Core founding and location facts are confirmed, but funding totals conflict between sources. Development claims are sourced from company and partner announcements.

Product and Technology

MIXED

Wave Therapeutics is developing a hardware-software system aimed at a persistent and costly clinical problem. The company's flagship product is the Wave Therapeutic Cushion, a smart cushioning device that integrates a microprocessor-controlled pump to automate two established medical therapies: pressure relief and sequential compression [Perplexity Sonar Pro Brief]. The core proposition is dynamic adjustment, moving beyond static foam or gel cushions to actively redistribute pressure and enhance blood flow in immobilized patients, thereby targeting the prevention of pressure injuries (bedsores) and deep vein thrombosis [wavetherapeuticsinc.com].

The technology is described as patent-pending, and the company has stated it is finalizing its design for manufacture with partner factories lined up [wavetherapeuticsinc.com] [ciconiamedical.com]. A key differentiator cited is the accompanying analytics platform, which allows for remote patient monitoring by clinical staff or family members to track compliance and pressure build-up [techpoint.org]. The company has also disclosed a collaboration with the Veterans Health Administration (VHA) Innovation Ecosystem and the Louis Stokes Cleveland VA Medical Center on the design and development of its initial wheelchair seat cushion product [rehabpub.com].

Future product iterations, described as a second generation, are planned to incorporate an array of sensors capable of detecting changes in skin temperature or pressure, moving the system further toward a predictive monitoring tool [techpoint.org]. Public materials frame the product as a cost-saving and liability-reducing device for institutional buyers like long-term care facilities and hospitals, while also being positioned for home health and broader mobility-impaired populations [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Product claims are sourced from the company website and partner announcements; technical readiness and sensor roadmap are from single-source trade coverage. The VHA collaboration is a named, public partnership.

Market Research

PUBLIC The economic and human cost of pressure injuries creates a persistent, high-stakes problem for healthcare providers, one that is intensifying as patient populations age and reimbursement models shift toward value-based care. The market for solutions to prevent these complications is defined by a significant, recurring financial burden on the healthcare system, driven by a combination of demographic trends, regulatory pressures, and the high cost of treatment after an injury occurs.

Third-party research on the specific market for smart therapeutic cushions is not publicly available. However, the scale of the underlying problem is well-documented. Multiple healthcare industry reports cite an annual incidence of more than 2.5 million pressure injuries in the United States [nethealth.com, 2026]; [ahrq.gov, 2026]; [rfhealth.com, 2026]. The associated cost to the U.S. healthcare system is consistently estimated in the range of $9.1 billion to $11.9 billion per year [nethealth.com, 2026]; [rfhealth.com, retrieved 2026]. One academic analysis suggests total costs could exceed $26.8 billion annually when accounting for all reported cases [pmc.ncbi.nlm.nih.gov, 2026]. The cost per individual case is substantial, with treatment adding between $20,000 and $151,000 to a patient's care per injury [nethealth.com, 2026]; [rfhealth.com, retrieved 2026].

Demand is anchored by several structural tailwinds. An aging population increases the at-risk cohort in long-term care and home health settings. Simultaneously, healthcare payment reform continues to penalize hospitals for hospital-acquired conditions (HACs), including pressure injuries, creating a direct financial incentive for prevention. The high cost of litigation and settlements related to pressure injuries further motivates facilities to adopt preventative technologies. Wave Therapeutics' stated expansion into occupational health for long-haul drivers and office workers suggests an adjacent market driven by employer-led wellness and productivity initiatives, though this remains a future-oriented claim without cited traction.

The primary substitute markets are traditional, passive pressure-relief surfaces (foam, gel, and air mattresses/cushions) and manual patient repositioning protocols performed by nursing staff. The competitive wedge for a smart cushion is its potential to automate a labor-intensive process, provide data-driven compliance monitoring, and theoretically improve outcomes beyond static solutions. Regulatory pathways for such a device as a Class II medical device would be a key macro force shaping time-to-market and capital requirements, though specific FDA clearance status for Wave's product is not cited in public sources.

Metric	Value
Annual U.S. Pressure Injury Incidence	2.5 million patients
Annual U.S. System Cost (Low Estimate)	9.1 $B
Annual U.S. System Cost (High Estimate)	11.9 $B
Cost Per Injury (Low Estimate)	20 $K
Cost Per Injury (High Estimate)	151 $K

The cited figures illustrate a market defined by severe economic pain. The wide range in per-injury cost estimates reflects variability in injury severity and care setting, but even the low end represents a significant avoidable expense. For a preventative solution, the relevant serviceable market is a fraction of this total cost burden, tied to the price point of the intervention and the addressable patient population.

Data Accuracy: YELLOW -- Market sizing figures are drawn from healthcare industry and government reports, not company claims, but specific application to the smart cushioning segment is inferred.

Competitive Landscape

MIXED Wave Therapeutics enters a market defined by established medical device incumbents, specialized niche players, and a growing field of digital health startups, with its competitive position resting on the integration of active pressure relief and remote monitoring into a single cushion.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Wave Therapeutics	Smart cushioning combining dynamic pressure relief, sequential compression, and remote analytics for pressure injury prevention.	Seed (~$1.6M) [PitchBook, retrieved 2024]	Integrates automated therapy with a patient-monitoring analytics platform.	[wavetherapeuticsinc.com, retrieved 2024]; [Perplexity Sonar Pro Brief]
Mölnlycke	Global medical solutions company offering a wide range of advanced wound care products, including static pressure-redistributing mattresses and overlays.	Public subsidiary of Investor AB.	Deep clinical evidence, global commercial scale, and a broad portfolio addressing wound care across the care continuum.	[Competitor data from structured facts]

Competition for pressure injury prevention splits into three distinct layers. The first is the static support surface segment, dominated by large medical supply companies like Mölnlycke, Hill-Rom (now part of Baxter), and Arjo. These firms offer a range of foam, gel, and air-filled mattresses and overlays that passively redistribute pressure. Their advantage is scale, reimbursement pathways, and entrenched relationships with group purchasing organizations (GPOs) in hospitals and long-term care. The second layer consists of active alternating pressure systems. These are more advanced devices, often featuring pumps that cycle air through mattress cells. They are typically rented for high-acuity patients and represent a more direct, though less intelligent, functional alternative to Wave's proposed technology. The third and most adjacent competitive set is the emerging digital health and remote patient monitoring (RPM) sector. Companies like EarlySense (continuous monitoring) or even smart wearable patches track vital signs but do not directly intervene with pressure relief, creating a potential partnership or substitution dynamic.

Wave's current defensible edge is conceptual rather than commercial, centering on its proposed integration of two proven therapies,automated pressure relief and sequential compression for circulation,with a software analytics layer. This combination, aimed at both preventing injuries and enabling compliance monitoring, is not commonly bundled in a single, smart cushion product targeted at the wheelchair and seated patient market [Perplexity Sonar Pro Brief]. This integration could be a durable wedge if it generates unique clinical data demonstrating reduced injury rates and lower total cost of care, which would be difficult for incumbents to replicate quickly without a ground-up redesign. However, this edge is highly perishable; it depends entirely on successful productization, regulatory clearance, and the generation of that clinical evidence before larger players with greater R&D budgets decide to build or acquire similar integrated solutions.

The company's most significant exposure is to the commercial and regulatory execution capabilities of the incumbents it seeks to displace. Mölnlycke and similar firms possess established FDA clearances for their devices, certified manufacturing quality systems, and dedicated sales forces that call directly on clinical facilities. Wave, as a pre-revenue startup with limited capital, lacks this commercial infrastructure and must either build a costly direct sales channel or secure a distribution partnership, which would cede margin and control. Furthermore, while the smart cushion targets wheelchair users, the vast majority of pressure injury prevention spend is on bed-based solutions for immobile patients. Wave's narrower initial focus limits its addressable market out of the gate, making it vulnerable if a broad-line incumbent launches a competing seated system leveraging its existing customer relationships.

The most plausible 18-month scenario hinges on Wave's ability to transition from prototype to a commercially cleared product with initial lighthouse customers. The winner in this scenario is a company like Wave if it can demonstrate a clear clinical benefit and cost-saving case in a pilot with a named healthcare system, such as its cited collaborator, the Veterans Health Administration [rehabpub.com, retrieved 2026]. Such validation would de-risk the technology for follow-on investors and potential distribution partners. The loser in this scenario is any startup in this space that fails to advance beyond the prototype stage or cannot secure a pivotal pilot, as the funding environment for medical hardware remains selective. Without a visible path to initial revenue, these companies risk being sidelined while incumbents iterate on their own product lines.

Data Accuracy: YELLOW -- Competitor identification is limited; Wave's positioning is based on company descriptions, while incumbent details are generalized from the sector.

Opportunity

PUBLIC The prize for Wave Therapeutics is a durable position within a multi-billion dollar healthcare cost center, replacing static, reactive care with a data-driven, preventative standard.

The headline opportunity is to become the default smart cushioning platform for pressure injury prevention in post-acute and long-term care settings. This outcome is reachable because the company is not inventing a new therapy, but automating and instrumenting two medically recognized ones: pressure relief and sequential compression. The core wedge is a cost-saving argument for facilities burdened by high treatment expenses and liability, a proposition supported by independent analyses of the pressure injury problem [nethealth.com, retrieved 2026] [rfhealth.com, retrieved 2026]. By integrating analytics for remote monitoring, the product shifts the value proposition from a passive piece of equipment to an active care management tool, aligning with broader healthcare trends toward value-based care and remote patient monitoring.

Growth scenarios outline concrete paths to scale beyond the initial clinical wedge. The company's public statements and development collaborations point toward three plausible expansion vectors.

Scenario	What happens	Catalyst	Why it's plausible
VA Standard of Care	The product is adopted across the Veterans Health Administration network for wheelchair-bound veterans.	Successful completion of the ongoing collaboration with the VHA Innovation Ecosystem and Louis Stokes Cleveland VA Medical Center [rehabpub.com, retrieved 2026].	The VA is a massive, integrated buyer with a clear mandate to improve veteran care and reduce long-term costs, making it an ideal lighthouse account.
Consumer & Occupational Health Pivot	A direct-to-consumer or employer-subsidized model emerges for office workers and long-haul drivers.	Launch of a second-generation cushion with embedded sensors for early pressure detection, as indicated in company statements [techpoint.org, retrieved 2026].	The company has explicitly mentioned expansion to these demographics [Perplexity Sonar Pro Brief, retrieved 2024], and the underlying technology is adaptable to seated environments beyond clinical settings.
Data Platform Monetization	The analytics backend becomes a reimbursable remote patient monitoring (RPM) service, sold separately to payers and health systems.	Securing a CPT code for RPM related to pressure injury prevention or demonstrating reduced readmissions in a pilot study.	The company notes its platform allows for remote monitoring by staff or family [techpoint.org, retrieved 2026], laying the foundational architecture for a software-as-a-medical-service model.

What compounding looks like is a classic hardware-enabled software flywheel. Each deployed cushion generates compliance and pressure data. In aggregate, this dataset can improve predictive algorithms for pressure injury risk, creating a clinical data moat. Better algorithms make the product more effective, driving further adoption. This adoption, in turn, strengthens distribution relationships with medical equipment suppliers and group purchasing organizations (GPOs), creating a distribution lock-in. Early signs of this flywheel are nascent but visible in the planned sensor integration for the second-generation product, which is explicitly designed to detect physiological changes [techpoint.org, retrieved 2026].

The size of the win can be framed by looking at comparable medical device companies focused on wound care and prevention. While direct public comps are scarce for a startup at this stage, the addressable market is substantiated by third-party research. Treating pressure injuries adds between $20,000 and $151,000 per injury to the cost of care [nethealth.com, retrieved 2026]. With the U.S. healthcare system spending an estimated $9.1 to $11.9 billion annually on the problem [nethealth.com, retrieved 2026] [rfhealth.com, retrieved 2026], a company that captures even a single-digit percentage of this spend through a combination of device sales and monitoring services could support a valuation in the hundreds of millions of dollars. In a VA Standard of Care scenario, capturing a meaningful portion of the VA's patient population could establish a revenue base sufficient to attract strategic acquirers in the durable medical equipment or digital health sectors.

Data Accuracy: YELLOW -- Growth scenarios are extrapolated from company statements and public collaborations; market cost data is from healthcare industry sources.

Sources

PUBLIC

1. [PitchBook, retrieved 2024] Wave Therapeutics 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/266971-24

2. [LinkedIn, retrieved 2024] Wave Therapeutics | https://www.linkedin.com/company/wavetherapeuticsinc

3. [Perplexity Sonar Pro Brief, retrieved 2024] Wave Therapeutics Brief |

4. [General Assembly, retrieved 2026] Jessica Bussert - General Assembly | https://generalassemb.ly/instructors/jessica-bussert/27256

5. [CB Insights, retrieved 2024] Wave Therapeutics Company Profile | https://www.cbinsights.com/company/wave-therapeutics

6. [wavetherapeuticsinc.com, retrieved 2024] Wave Therapeutics | https://wavetherapeuticsinc.com/

7. [techpoint.org, retrieved 2026] Wave Therapeutics coverage |

8. [ciconiamedical.com, retrieved 2026] Meet the 10 MedTech Startups Graduating from the 2023 mHUB Accelerator | https://www.ciconiamedical.com/news/meet-the-10-medtech-startups-graduating-from-the-2023-mhub-accelerator

9. [rehabpub.com, retrieved 2026] Wave Therapeutics collaboration with VHA |

10. [nethealth.com, retrieved 2026] Pressure Injury Market Data |

11. [ahrq.gov, retrieved 2026] Pressure Injury Market Data |

12. [rfhealth.com, retrieved 2026] Pressure Injury Market Data |

13. [pmc.ncbi.nlm.nih.gov, retrieved 2026] Pressure Injury Cost Analysis |

14. [mhub.org, retrieved 2026] Meet the 10 MedTech Startups Graduating from the 2023 mHUB Accelerator | https://mhub.org/blog/meet-the-medtech-startups-graduating-from-the-2023-mhub-accelerator